Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Must- Read Articles
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Must- Read Articles
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Article

UCP2 Knockout Suppresses Mouse Skin Carcinogenesis

Wenjuan Li, Chunjing Zhang, Kasey Jackson, Xingui Shen, Rong Jin, Guohong Li, Christopher G. Kevil, Xin Gu, Runhua Shi and Yunfeng Zhao
Wenjuan Li
1Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
2School of Basic Medicine, Hebei University, Baoding, Hebei, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunjing Zhang
1Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
3School of Basic Medicine, Qiqihar Medical University, Qiqihar, Heilongjiang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kasey Jackson
1Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xingui Shen
4Department of Pathology, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rong Jin
5Department of Neurosurgery, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guohong Li
5Department of Neurosurgery, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher G. Kevil
4Department of Pathology, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin Gu
4Department of Pathology, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Runhua Shi
6Feist-Weiller Cancer Center, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunfeng Zhao
1Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yzhao1@lsuhsc.edu
DOI: 10.1158/1940-6207.CAPR-14-0297-T Published June 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Mitochondrial uncoupling (uncouples electron transport from ATP production) has recently been proposed as a novel survival mechanism for cancer cells, and reduction in free radical generation is the accepted mechanism of action. However, there is no direct evidence supporting that uncoupling proteins promote carcinogenesis. Herein, we examined whether mitochondrial uncoupling affects mouse skin carcinogenesis using uncoupling protein 2 (UCP2) homozygous knockout and wild-type mice. The results indicate that knockout of Ucp2 significantly reduced the formation of both benign (papilloma) and malignant (squamous cell carcinoma) tumors. UCP2 knockout did not cause increases in apoptosis during skin carcinogenesis. The rates of oxygen consumption were decreased only in the carcinogen-treated UCP2 knockout mice, whereas glycolysis was increased only in the carcinogen-treated wild-type mice. Finally, the levels of metabolites pyruvate, malate, and succinate showed different trends after carcinogen treatments between the wild-type and UCP2 knockout mice. Our study is the first to demonstrate that Ucp2 knockout suppresses carcinogenesis in vivo. Together with early studies showing that UCP2 is overexpressed in a number of human cancers, UCP2 could be a potential target for cancer prevention and/or therapy. Cancer Prev Res; 8(6); 487–91. ©2015 AACR.

Introduction

The mitochondrion is the major source of adenosine triphosphate (ATP) in eukaryotes, which is generated via a proton gradient across the mitochondrial inner membrane (Δψm). However, not all of the energy available in the electrochemical gradient is coupled to ATP synthesis. A portion of the energy is consumed by “proton leak” reactions. As a result, the energy derived from the metabolic oxidation reaction is dissipated as heat (1–4). This phenomenon is called “mitochondrial uncoupling.” Mitochondrial uncoupling is caused mainly by uncoupling proteins (UCP) at physiological conditions. Among the five isoforms of UCPs, UCP2 is ubiquitously expressed and has been found to be upregulated in human tumor tissues (5–7).

In cancer cells, it has been suggested that high levels of mitochondrial uncoupling provide a prosurvival advantage to these tumor cells (5, 8). This prosurvival advantage is accomplished via two mechanisms: attenuating ROS (reactive oxygen species) generation (9–11) and reprogramming of cancer cell metabolism (12). In cancer cells, ROS are involved in the regulation of many physiological processes, which promotes further genomic instability and in the upregulation of signaling pathways of cellular growth and proliferation. However, if produced excessively, ROS may also be harmful to the cell by initiating cell death pathways (13). Hence, a well-controlled ROS level in cancer cells is important for tumor cell physiology, growth, and survival (14, 15). Mitochondrial uncoupling has been suggested to have a natural antioxidant effect that increases respiratory rates and thus attenuates ROS generation. Cancer cells also change their metabolic behaviors toward glycolysis and lactate fermentation for ATP production even under ample supply of oxygen (Warburg effect). Because mitochondria are debilitated, upregulation of UCP2 forces the cell to undergo aerobic glycolysis, in order to produce sufficient energy. The Warburg effect produces ATP less efficiently than oxidative phosphorylation but at a faster rate, promoting cells to proliferate at an increased rate and keep its oversupply of UCP2.

All of these observations suggest that UCP2 can promote cancer development. However, to date, there is no direct evidence supporting this role of UCP2. Utilizing the well-characterized mouse skin carcinogenesis model, whether knockout (KO) of UCP2 suppresses skin carcinogenesis will be studied.

Materials and Methods

Reagents and animals

7,12-dimethylbenz[α]anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) were purchased from Sigma. Both reagents were dissolved in dimethyl sulfoxide (DMSO; Sigma).

Six- to 8-week-old female UCP2 homozygous KO mice (ucp2−/−) and wild-type (WT) C57BL/6 mice were purchased from the Jackson Laboratory (stock number: 005934, in C57BL/6 background).

Multistage skin carcinogenesis

The animal study was performed under the approved animal protocol by the Institutional Animal Care and Use Committee of the LSU Health Sciences Center in Shreveport (Shreveport, LA). UCP2 and WT C57BL/6 mice were separated into four groups: (i) WT + vehicle (DMSO): 8 mice; (ii) UCP2 KO + vehicle (DMSO): 8 mice; (iii) WT + DMBA/TPA: 13 mice; (iv) UCP2 KO + DMBA/TPA: 18 mice. Hair on the back was shaven 2 days before treatments. For groups (i) and (ii), a single topical application of 200 μL of DMSO was performed once per day, five times a week for 40 weeks. For groups (iii) and (iv), a single dose of 400 nmol/L of DMBA was topically applied. Two weeks later, a single topical application of 5 μg TPA was performed once per day, 5 days per week for 40 weeks. At the end of the study, mice were euthanized by injecting overdosed pentobarbital (150 mg/kg). The skin tissues were removed, and the following steps were conducted: several small pieces of the non-tumor epidermal tissues were fixed; the remaining non-tumor epidermal tissues were stripped off and frozen for biochemical studies; the remaining skin tissues with tumors were fixed in Karnovsky's fixative for pathologic examinations. A pathologist (X. Gu) examined skin tumor formation of these tumor-bearing tissues.

Counting apoptotic and mitotic cells

Skin epidermal tissues were fixed in 4% buffered formaldehyde, embedded in paraffin, and processed for hematoxylin and eosin (H&E) stain. Mitotic and apoptotic cells were counted via light microscopic evaluation. Morphologic features, such as cell shrinkage, nuclear condensation, and formation of cytoplasmic vacuoles, were used to identify apoptosis. All phases of mitosis were included. Morphologic analysis was supervised by a certified pathologist (X. Gu).

Measurements of oxygen consumption of skin cells stripped from mouse skin epidermal tissues

Skin epidermal cells were collected as described previously (16). Stripped skin cells were resuspended in mitochondrial isolation buffer (0.225 mol/L mannitol, 0.075 mol/L sucrose, 1 mmol/L EGTA, pH 7.4) and transferred into a thermostated closed vessel at 37°C. Oxygen consumption was measured polarographically using a Clark-type O2 electrode (Yellow Spring Instruments). The rate of mitochondrial O2 consumption was determined as the cyanide-sensitive rate.

Preparation of whole cell lysate

Collected skin cells were suspended in 250 μL of PBS containing a proteinase inhibitor cocktail (Calbiochem). Cells were sonicated on ice for two strokes (10 seconds per stroke) using a Fisher Sonic Dismembrator (model 100, scale 4). After incubating on ice for 30 minutes, cell lysate was centrifuged at 18,000 × g for 20 minutes, and the supernatant was collected and designated as whole cell lysate.

Determination of pyruvate, malate, and succinate by high-performance liquid chromatography

The Shimadzu high-performance liquid chromatography (HPLC) system consisted of a binary, high-pressure gradient solvent delivery pump (model LC 20AB), an autosampler equipped with a cooling sample device (model SIL-20AC HT), a UV-visible absorbance detector (model SPD-20A), and data processing software (LCsolution version 1.23). The settings of the machine and sample preparation have been described previously (16).

Determination of ATP levels

The levels of ATP were determined using the ATP Assay Kit (BioVison, K354-100) following the instructions provided by the manufacturer. Whole cell lysate from mouse skin tissues was diluted to 2 μg/μL in PBS and deproteinized by passing through a 10-kD cutoff membrane (VWR, 82031-348). For each sample, 50 μL of the whole cell lysate filtrate was used.

Detection of lactate levels

The levels of lactate were determined using the Lactate Assay Kit (BioVison, K607-100) following the instructions provided by the manufacturer. Whole cell lysate was diluted to 2 μg/μL in PBS and deproteinized by passing through a 10-kD cutoff membrane (VWR, 82031-348). For each sample, 50 μL of the whole cell lysate filtrate was used.

Statistical analysis

Incidence expressed as percent was computed as the number of mice with tumor divided by the number of mice in that group. Data were presented as mean and SD. The nonparametric method exact Wilcoxon test was used to compare the tumor multiplicity. The Fisher exact test was used to compare the tumor incidence. Statistical software SAS 9.4 (SAS Institute Inc.) was used for all data analysis, and two-sided P < 0.05 was considered statistically significant.

Results and Discussion

To explore whether mitochondrial uncoupling affects skin carcinogenesis, we performed the animal study by using uncoupling protein 2 (UCP2) homozygous KO and WT mice. The animal bodyweights were recorded at the end of the study, and the results were as follows: WT/DMSO group: 22.4 ± 2.5 g (mean ± SD); WT/TPA group: 22.6 ± 1.7 g; UCP2-KO/DMSO group: 25.9 ± 2.0 g; and UCP2-KO/TPA group: 25.9 ± 2.5 g. The UCP2 mice weighed more than the WT mice in both DMSO-treated (P = 0.01) and TPA-treated (P = 0.0002) groups; however, TPA treatment did not significantly affect bodyweights. Because the skin carcinogenesis study has been performed for 40 weeks, both benign (papilloma) and malignant (squamous cell carcinoma) tumors have developed. Representative images of H&E-stained skin epidermal tissues/tumors are shown in Fig. 1. The data on tumor incidence and multiplicity are summarized in Table 1. Using the two-sided Fisher exact test, the difference in the incidences of papillomas between WT and UCP2 KO mice was not significant (P = 0.3679), whereas the difference in the incidences of carcinomas between WT and KO was significant (P = 0.0040). Using the exact Wilcoxon test to compare tumor multiplicity between WT and KO groups, both the differences in papillomas and carcinomas were significant (P = 0.0084 and 0.0023, respectively).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Representative H&E-stained mouse skin epidermal tissues/tumors at the end of the skin carcinogenesis study. Each sample represented one treatment group. A, WT/DMSO, amplification 10×; B, WT/TPA, amplification 2×; C, UCP2 KO/DMSO, amplification 10×; D, UCP2 KO/TPA, amplification 2×. A squamous cell carcinoma is shown in B and a papilloma is shown in D.

View this table:
  • View inline
  • View popup
Table 1.

Skin tumor formation in the multistage carcinogenesis model

Next, the mitotic and apoptotic index in mouse skin epidermal was assessed by morphologic determination. As summarized in Table 2, both mitosis and apoptosis were increased in WT mice by carcinogen treatments. Mitosis was marginally increased in UCP2 KO mice (P = 0.076), and apoptosis was not significantly changed in these mice after carcinogen treatments. Similar results were obtained from immunohistochemical staining of the skin epidermal tissues (Supplementary Fig. S1). The WT/TPA group showed higher Ki-67 and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining, whereas the rest three groups (WT/DMSO, UCP2 KO/DMSO, and UCP2 KO/TPA) showed similar and lower levels of Ki-67 and TUNEL staining.

View this table:
  • View inline
  • View popup
Table 2.

Mitosis and apoptosis index in the multistage carcinogenesis model

The levels of mitochondrial oxygen consumption and ATP production were measured using stripped skin cells collected at the end of the skin carcinogenesis study. As shown in Fig. 2A, although there appeared a slight increase in the levels of oxygen consumption in the vehicle-treated UCP2 group compared with the WT group similarly treated, the difference was not significant (P = 0.81). Carcinogen treatments did not cause a significant change in oxygen consumption levels in the WT mice (P = 0.77), but induced a significant decrease in the UCP2 KO group. ATP production (Fig. 2B) was not significantly different between WT and UCP2 KO groups, and between vehicle- and carcinogen-treated groups. It has been demonstrated that upregulated UCP2 promotes aerobic glycolysis of cancer cells, which is accompanied by an increase in lactate production (16). Thereafter, lactic acid levels were measured using mouse skin epidermal tissues mentioned above. The results (Fig. 2C) showed that lactate generation was significantly increased in the carcinogen-treated WT mice, but there was no difference between carcinogen-treated and vehicle-treated UCP2 KO mice.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

The levels of mitochondrial oxygen consumption, not ATP production, were significantly decreased only in UCP2 KO mice after carcinogen treatment; lactate generation was significantly increased only in the WT mice after carcinogen treatment. A, measurement of oxygen consumption using stripped skin epidermal cells. B, the levels of ATP and lactate (C) were determined using whole cell lysate from stripped skin epidermal cells. KO, UCP2 KO. n = 8 per group; data, mean ± SEM. *, P < 0.05, compared with the DMSO group.

Because UCP2 has been recently shown to be able to transport C4 tricarboxylic acid (TCA) cycle intermediates (17), the skin epidermal tissue levels of pyruvate, malate, and succinate were detected, and the results are summarized in Table 3. In WT animals, carcinogen treatments increased the tissue levels of pyruvate and malate but decreased the levels of succinate, whereas in UCP2 KO animals, the levels of these metabolites had little or no change. These results were associated with the expression levels of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2) in each treatment group (Supplementary Fig. S2). PFKFB2 belongs to a family of the bifunctional enzyme PFKFB that controls the levels of fructose 2,6-bisphosphate (F2,6BP). F2,6BP in turn activates the rate-limiting enzyme of glycolysis: phosphofructokinase-1 (PFK-1). PFKFB2 has been shown to be highly expressed in human liver (18), thyroid (19), and leukemia (20) tumor tissues, and PFKFB has become a molecular target in the development of anticancer drugs (21). Future studies will be performed to examine whether UCP2-transported TCA cycle intermediates regulate PFKFB2 expression and/or activity.

View this table:
  • View inline
  • View popup
Table 3.

Levels of pyruvate, malate, and succinate in skin epidermal tissues (μg/mL)

Inflammation also contributes to skin carcinogenesis. Does UCP2 affect cutaneous inflammatory response? As shown in Supplementary Fig. S3, neutrophils infiltration around the invaded tumors was identified in the WT mice treated by carcinogens, which was not clearly observed in skin tumors from the UCP2 KO group. This result suggests that UCP2 may contribute to cutaneous inflammation, which provides another potential mechanism of how UCP2 promotes carcinogenesis.

As an anion carrier, UCP2 has also been found to play a role in several metabolic processes, including insulin secretion (22) and lipid/glucose metabolism (23). Not surprising, UCP2 has been suggested to be involved in a few metabolic diseases, such as obesity, diabetes, and cancer. Upregulation of UCP2 has been reported in human colon (5) and breast (7) cancers. Our recent studies also reveal that UCP2 is overexpressed in human skin, head and neck, pancreatic, and prostate tumor tissues compared with the adjacent normal tissues (6). It has been proposed that upregulation of UCP2 may serve as a novel survival mechanism for cancer cells, which is thought to be mediated by lowering ROS generation (24). However, there is no direct evidence supporting that UCP2 promotes carcinogenesis.

This article provides the first in vivo evidence using UCP2 mice supporting that UCP2 promotes carcinogenesis. Although the current data are unable to answer the question of how UCP2 KO suppresses skin cancer formation, the apoptosis index study suggests that UCP2 KO does not promote apoptosis during skin carcinogenesis. An interesting and important finding is the adverse changes of the three metabolites during carcinogenesis, which provides a clue for future studies.

Disclosure of Potential Conflicts of Interest

C. Kevil reports receiving commercial research support from Faraday Pharmaceutical and has ownership interest (including patents) in Theravasc, Inc. and Innolyzer LLC. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: C. Zhang, R. Shi, Y. Zhao

Development of methodology: W. Li, X. Shen, C.G. Kevil, Y. Zhao

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K. Jackson, X. Shen, C.G. Kevil, X. Gu, Y. Zhao

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W. Li, X. Shen, G. Li, X. Gu, R. Shi, Y. Zhao

Writing, review, and/or revision of the manuscript: W. Li, X. Shen, R. Shi, Y. Zhao

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): W. Li, R. Jin, G. Li

Study supervision: Y. Zhao

Grant Support

This study was supported by NIH grant number 1R03CA167689 (Y. Zhao) NS088719 (G. Li), HL113303 (C.G. Kevil) and R21CA164218 (Y. Zhao).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors thank Paul Polk at the Research Core Facility of their institution for technical support.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Prevention Research Online (http://cancerprevres.aacrjournals.org/).

  • Received September 9, 2014.
  • Revision received January 30, 2015.
  • Accepted March 9, 2015.
  • ©2015 American Association for Cancer Research.

References

  1. 1.↵
    1. Brand MD
    . The proton leak across the mitochondrial innermembrane. Biochim Biophys Acta 1990;1018:128–33.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Brand MD,
    2. Chien LF,
    3. Ainscow EK,
    4. Rolfe DFS,
    5. Porter RK
    . The causes and functions of mitochondrial proton leak. Biochim Biophys Acta 1994;1187:132–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Brown GC,
    2. Brand MD
    . On the nature of the mitochondrial proton leak. Biochim Biophys Acta 1991;1059:55–62.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Brand MD,
    2. Brindle KM,
    3. Buckingham JA,
    4. Harper JA,
    5. Rolfe DFS,
    6. Stuart JA
    . The significance and mechanism of mitochondrial proton conductance. Int J Obes Relat Metab Disord 1999;23:S4–S11.
    OpenUrl
  5. 5.↵
    1. Horimoto M,
    2. Resnick MB,
    3. Konkin TA,
    4. Routhier J,
    5. Wands JR,
    6. Baffy G
    . Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res 2004;10:6203–7.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Sayeed A,
    2. Meng Z,
    3. Luciani G,
    4. Chen LC,
    5. Bennington JL,
    6. Dairkee SH
    . Negative regulation of UCP2 by TGFβ signaling characterizes low and intermediate-grade primary breast cancer. Cell Death Dis 2010;1:e53.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Li W,
    2. Nicholas K,
    3. Nathan CA,
    4. Zhao Y
    . Mitochondrial uncoupling protein 2 is up-regulated in human head and neck, skin, pancreatic, and prostate tumors. Cancer Biomark 2013;13:377–83.
    OpenUrlPubMed
  8. 8.↵
    1. Harper ME,
    2. Antoniou A,
    3. Villalobos-menuey E,
    4. Russo A,
    5. Trauger R,
    6. Vendemelio M,
    7. et al.
    Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J 2002;16:1550–7.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Nègre-Salvayre A,
    2. Hirtz C,
    3. Carrera G,
    4. Cazenave R,
    5. Troly M,
    6. Salvayre R,
    7. et al.
    A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. FASEB J 1997;11:809–15.
    OpenUrlAbstract
  10. 10.↵
    1. Kowaltowski AJ,
    2. Costa AD,
    3. Vercesi AE
    . Activation of the potato plant uncoupling mitochondrial protein inhibits reactive oxygen species generation by the respiratory chain. FEBS Lett 1998;425:213–6.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Kowaltowski AJ,
    2. de Souza-Pinto NC,
    3. Castilho RF,
    4. Vercesi AE
    . Mitochondria and reactive oxygen species. Free Radic Bio Med 2009;47:333–43.
    OpenUrlCrossRef
  12. 12.↵
    1. Samudio I,
    2. Fiegl M,
    3. Andreeff M
    . Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 2009;69:2163–6.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Schumacker PT
    . Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006;10:175–6.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Nelson KK,
    2. Melendez JA
    . Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004;37:768–84.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Halliwell B
    . Oxidative stress and cancer: have we moved forward? Biochem J 2007;401:1–11.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Wittwer JA,
    2. Robbins D,
    3. Wang F,
    4. Codarin S,
    5. Shen X,
    6. Kevil CG,
    7. et al.
    Enhancing mitochondrial respiration suppresses tumor promoter TPA-induced PKM2 expression and cell transformation in skin epidermal JB6 cells. Cancer Prev Res 2011;4:1476–84.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Vozza A,
    2. Parisi G,
    3. De Leonardis F,
    4. Lasorsa FM,
    5. Castegna A,
    6. Amorese D,
    7. et al.
    UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation. Proc Natl Acad Sci U S A 2014;111:960–5.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Ji D,
    2. Lu ZT,
    3. Li YQ,
    4. Liang ZY,
    5. Zhang PF,
    6. Li C,
    7. et al.
    MACC1 expression correlates with PFKFB2 and survival in hepatocellular carcinoma. Asian Pac J Cancer Prev 2014;15:999–1003.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Vriens MR,
    2. Moses W,
    3. Weng J,
    4. Peng M,
    5. Griffin A,
    6. Bleyer A,
    7. et al.
    Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer 2011;117:259–67.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Schmidt S,
    2. Rainer J,
    3. Riml S,
    4. Ploner C,
    5. Jesacher S,
    6. Achmller C,
    7. et al.
    Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 2006;107:2061–9.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Yalcin A,
    2. Telang S,
    3. Clem B,
    4. Chesney J
    . Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 2009;86:174–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Pi J,
    2. Bai Y,
    3. Daniel KW,
    4. Liu D,
    5. Lyght O,
    6. Edelstein D,
    7. et al.
    Persistent oxidative stress due to absence of uncoupling protein 2 associated with impaired pancreatic beta-cell function. Endocrinology 2009;150:3040–8.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Andrews ZB,
    2. Liu ZW,
    3. Walllingford N,
    4. Erion DM,
    5. Borok E,
    6. Friedman JM,
    7. et al.
    UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 2008;454:846–51.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Baffy G
    . Uncoupling protein-2 and cancer. Mitochondrion 2010;10:243–52.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Prevention Research: 8 (6)
June 2015
Volume 8, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
UCP2 Knockout Suppresses Mouse Skin Carcinogenesis
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
UCP2 Knockout Suppresses Mouse Skin Carcinogenesis
Wenjuan Li, Chunjing Zhang, Kasey Jackson, Xingui Shen, Rong Jin, Guohong Li, Christopher G. Kevil, Xin Gu, Runhua Shi and Yunfeng Zhao
Cancer Prev Res June 1 2015 (8) (6) 487-491; DOI: 10.1158/1940-6207.CAPR-14-0297-T

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
UCP2 Knockout Suppresses Mouse Skin Carcinogenesis
Wenjuan Li, Chunjing Zhang, Kasey Jackson, Xingui Shen, Rong Jin, Guohong Li, Christopher G. Kevil, Xin Gu, Runhua Shi and Yunfeng Zhao
Cancer Prev Res June 1 2015 (8) (6) 487-491; DOI: 10.1158/1940-6207.CAPR-14-0297-T
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Oral Health and Upper Gastrointestinal Cancers
  • HCC Early Detection
  • Utility of Germline SNPs in Prostate Cancer Diagnosis
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement